3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
5
Head & Neck
1
Gynecologic
1
Dermatologic
1
Breast
1
Conditions
Head and Neck Neoplasms
7
Neoplasms
3
Thyroid Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Hypoparathyroidism
2
Carcinoma, Squamous Cell
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Diseases
1
Recurrence
1
Rectal Neoplasms
1
Parathyroid Diseases
1
Ovarian Neoplasms
1
Neovascularization, Pathologic
1
Melanoma
1
Margins of Excision
1
Lymphedema
1
Head and Neck Carcinoma
1
Graves Disease
1
Goiter
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Anus Neoplasms
1
Adenoma
1
Interventions
Cetuximab
4
pembrolizumab
3
Trastuzumab
3
Radiotherapy
3
Erlotinib Hydrochloride
3
Tomography, X-Ray Computed
2
Magnetic Resonance Spectroscopy
2
Fluorodeoxyglucose F18
2
Docetaxel
2
Biopsy
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
tipifarnib
1
sargramostim
1
sapanisertib
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
oblimersen
1
nanocis
1
mercaptoundecahydrododecaborate
1
larotrectinib
1
ipatasertib
1
fluoromisonidazole
1
erythromycin propionate-N-acetylcysteinate
1
erdafitinib
1
entinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rectal Neoplasms
×
Indocyanine Green
×
Head & Neck
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled